Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Audentes Therapeutics, Inc. (NASDAQ: BOLD).

Full DD Report for BOLD

You must become a subscriber to view this report.

Recent News from (NASDAQ: BOLD)

Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space
Stock Research Monitor: AVEO, CLDX, and CERS LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at . On Thursday, May 17, 2018, the NASDAQ Composite ended the trading session at 7,382.47, d...
Date: May, 18 2018 07:05
Your Daily Pharma Scoop: Loxo Outstanding Results, Cimzia Trial Success, Audentes Positive Data
Analysis focus: LOXO Loxo Oncology (LOXO), which was recently covered in a series of excellent articles by our very own Dr. Zach Hartman, PhD, who collaborates with the Total Pharma Tracker and whose members saw an early view of the series (...and so on), is up strongly “following...
Source: SeekingAlpha
Date: May, 17 2018 12:00
Audentes reports positive results from study of AT132 in XLMTM; shares up 7%
Thinly traded Audentes Therapeutics ( BOLD +6.6% ) is up on more than double normal volume on the heels of its announcement of continued positive results from its Phase 1/2 clinical trial, ASPIRO, assessing gene therapy AT132 in patients with X-Linked Myotubular Myopathy (XLMTM), an inhe...
Source: SeekingAlpha
Date: May, 16 2018 12:15
Bluebird Bio: Gene Therapy Best In Class
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two...
Source: SeekingAlpha
Date: May, 16 2018 11:31
Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
SAN FRANCISCO , May 16, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced continuing positive data ...
Source: PR Newswire
Date: May, 16 2018 11:30
Genomic Medicine: Catch The Gene Therapy Wave
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project “HGP” this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, Genomic medicine is showing signs of being the transformative for...
Source: SeekingAlpha
Date: May, 14 2018 15:12
Audentes Therapeutics: Key Program Updates
Most small-cap biotech quarterly earnings releases are irrelevant and provide very little insight beyond a vague program update and a quick snap shot of cash burn. In fact, most small biotech firms don't even hold quarterly conference calls, because they have no new data or information to rele...
Source: SeekingAlpha
Date: May, 12 2018 06:15
Key events next week - healthcare
Noteworthy events during the week of May 13 - 19 for healthcare investors: More news on: Ovid Therapeutics Inc., Evolus, Inc., Allergan plc, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 11 2018 12:02
Wired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNP
Stock Monitor: Audentes Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Ascendis Pharma A/S (NASDAQ: ASND ), all you need to do is sign up now by clicking the following link
Date: May, 10 2018 07:25
Audentes Therapeutics' (BOLD) CEO Matt Patterson on Q1 2018 Results - Earnings Call Transcript
Start Time: 16:30 End Time: 17:23 Audentes Therapeutics, Inc. (BOLD) Q1 2018 Earnings Conference Call May 09, 2018, 16:30 PM ET Executives Matt Patterson - President and CEO Tom Soloway - SVP and CFO Natalie Holles - President and COO Suyash Prasad - SVP and CMO Andrew Ch...
Source: SeekingAlpha
Date: May, 09 2018 23:03


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BOLD.

About Audentes Therapeutics, Inc. (NASDAQ: BOLD)

Logo for Audentes Therapeutics, Inc. (NASDAQ: BOLD)

Not available


Contact Information



Current Share Structure

  • Market Cap: $1,254,258,563 - 05/11/2018
  • Issue and Outstanding: 36,674,227 - 03/05/2018


Recent Filings from (NASDAQ: BOLD)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 23 2018
Automatic shelf registration statement of securities of well-known seasoned issuers
Filing Type: S-3ASRFiling Source: edgar
Filing Date: March, 29 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018



Daily Technical Chart for (NASDAQ: BOLD)

Daily Technical Chart for (NASDAQ: BOLD)

Stay tuned for daily updates and more on (NASDAQ: BOLD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BOLD)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BOLD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BOLD and does not buy, sell, or trade any shares of BOLD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: